Ignite Creation Date:
2025-12-26 @ 10:36 AM
Ignite Modification Date:
2025-12-26 @ 10:36 AM
Study NCT ID:
NCT05543928
Status:
TERMINATED
Last Update Posted:
2025-07-25
First Post:
2022-09-13
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D014808', 'term': 'Vitamin D Deficiency'}, {'id': 'D006962', 'term': 'Hyperparathyroidism, Secondary'}], 'ancestors': [{'id': 'D001361', 'term': 'Avitaminosis'}, {'id': 'D003677', 'term': 'Deficiency Diseases'}, {'id': 'D044342', 'term': 'Malnutrition'}, {'id': 'D009748', 'term': 'Nutrition Disorders'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D006961', 'term': 'Hyperparathyroidism'}, {'id': 'D010279', 'term': 'Parathyroid Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'contact@opko.com', 'phone': '3055754100', 'title': 'OPKO Health Inc', 'organization': 'OPKO Health Inc'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'description': 'The study was terminated before randomization', 'eventGroups': [{'id': 'EG000', 'title': 'Cohort 1 and Cohort 2 Placebo', 'description': 'Placebo: Placebo', 'otherNumAtRisk': 0, 'deathsNumAtRisk': 0, 'otherNumAffected': 0, 'seriousNumAtRisk': 0, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Cohort 1 and Cohort 2 CTAP101 Capsule', 'description': 'CTAP101: CTAP101 Capsules is an extended-release (ER) oral formulation of calcifediol which was approved as Rayaldee® ER Capsules in June 2016 by the United States (US) Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI), defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL.', 'otherNumAtRisk': 0, 'deathsNumAtRisk': 0, 'otherNumAffected': 0, 'seriousNumAtRisk': 0, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Numbers of Subjects Who Attained Mean Decrease in Plasma iPTH of 30% From Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1 and Cohort 2 Placebo', 'description': 'Placebo: Placebo'}, {'id': 'OG001', 'title': 'Cohort 1 and Cohort 2 CTAP101 Capsule', 'description': 'CTAP101: CTAP101 Capsules is an extended-release (ER) oral formulation of calcifediol which was approved as Rayaldee® ER Capsules in June 2016 by the United States (US) Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI), defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL.'}], 'timeFrame': '26 weeks', 'description': 'The primary efficacy endpoint is the proportion of subjects in the intent-to- treat (ITT) population (age 8 to \\<18 years) attaining a mean decrease in plasma iPTH of at least 30% from pre-treatment baseline compared to placebo during the EAP.', 'reportingStatus': 'POSTED', 'populationDescription': 'The study was terminated before randomization'}, {'type': 'PRIMARY', 'title': 'Safety and Tolerability', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1 and Cohort 2 Placebo', 'description': 'Placebo: Placebo'}, {'id': 'OG001', 'title': 'Cohort 1 and Cohort 2 CTAP101 Capsule', 'description': 'CTAP101: CTAP101 Capsules is an extended-release (ER) oral formulation of calcifediol which was approved as Rayaldee® ER Capsules in June 2016 by the United States (US) Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI), defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL.'}], 'timeFrame': '26 weeks', 'description': 'Safety and tolerability will be evaluated in the safety population by AEs, PEs, VS, hematology and laboratory evaluations, and ECGs.', 'reportingStatus': 'POSTED', 'populationDescription': 'The study was terminated before randomization'}, {'type': 'PRIMARY', 'title': 'Pharmacokinetic', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1 and Cohort 2 Placebo', 'description': 'Placebo: Placebo'}, {'id': 'OG001', 'title': 'Cohort 1 and Cohort 2 CTAP101 Capsule', 'description': 'CTAP101: CTAP101 Capsules is an extended-release (ER) oral formulation of calcifediol which was approved as Rayaldee® ER Capsules in June 2016 by the United States (US) Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI), defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL.'}], 'timeFrame': '26 weeks', 'description': 'To assess the pharmacokinetic (PK) profile of 25-hydroxyvitamin D3 after repeated doses of CTAP101 Capsules in pediatric subjects', 'reportingStatus': 'POSTED', 'populationDescription': 'The study was terminated before randomization'}, {'type': 'SECONDARY', 'title': 'Level of Serum Total 25-hydroxyvitamin D at ≥30 ng/mL Compared to Placebo', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1 and Cohort 2 Placebo', 'description': 'Placebo: Placebo'}, {'id': 'OG001', 'title': 'Cohort 1 and Cohort 2 CTAP101 Capsule', 'description': 'CTAP101: CTAP101 Capsules is an extended-release (ER) oral formulation of calcifediol which was approved as Rayaldee® ER Capsules in June 2016 by the United States (US) Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI), defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL.'}], 'timeFrame': '26 weeks', 'description': 'To evaluate the efficacy of repeated dosing with CTAP101 Capsules versus placebo in raising serum total 25-hydroxyvitamin D to ≥30 ng/mL', 'reportingStatus': 'POSTED', 'populationDescription': 'The study was terminated before randomization'}, {'type': 'SECONDARY', 'title': 'Plasma iPTH Mean Absolute Changes and Serum Total 25-hydroxyvitamin D', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1 and Cohort 2 Placebo', 'description': 'Placebo: Placebo'}, {'id': 'OG001', 'title': 'Cohort 1 and Cohort 2 CTAP101 Capsule', 'description': 'CTAP101: CTAP101 Capsules is an extended-release (ER) oral formulation of calcifediol which was approved as Rayaldee® ER Capsules in June 2016 by the United States (US) Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI), defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL.'}], 'timeFrame': '26 weeks', 'description': 'To determine the time courses of mean absolute changes from pre-treatment baseline in serum total 25-hydroxyvitamin D and plasma iPTH during administration of repeated doses of CTAP101 Capsules', 'reportingStatus': 'POSTED', 'populationDescription': 'The study was terminated before randomization'}, {'type': 'SECONDARY', 'title': 'Pharmacodynamic Effects of Repeated Doses of CTAP101 Capsules', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1 and Cohort 2 Placebo', 'description': 'Placebo: Placebo'}, {'id': 'OG001', 'title': 'Cohort 1 and Cohort 2 CTAP101 Capsule', 'description': 'CTAP101: CTAP101 Capsules is an extended-release (ER) oral formulation of calcifediol which was approved as Rayaldee® ER Capsules in June 2016 by the United States (US) Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI), defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL.'}], 'timeFrame': '26 weeks', 'description': 'To assess the PD effects of repeated doses of CTAP101 Capsules versus placebo on mean serum calcium (corrected for albumin), serum phosphorus and serum calcium-times-phosphorus (CaxP) product, and the change in mean urine calcium:creatinine ratio', 'reportingStatus': 'POSTED', 'populationDescription': 'The study was terminated before randomization'}, {'type': 'SECONDARY', 'title': 'Incidence of Hypercalcemia and Hyperphosphatemia', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Cohort 1 and Cohort 2 Placebo', 'description': 'Placebo: Placebo'}, {'id': 'OG001', 'title': 'Cohort 1 and Cohort 2 CTAP101 Capsule', 'description': 'CTAP101: CTAP101 Capsules is an extended-release (ER) oral formulation of calcifediol which was approved as Rayaldee® ER Capsules in June 2016 by the United States (US) Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI), defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL.'}], 'timeFrame': '26 weeks', 'description': 'To evaluate the safety of CTAP101 Capsules versus placebo with regard to the incidence of hypercalcemia and hyperphosphatemia', 'reportingStatus': 'POSTED', 'populationDescription': 'The study was terminated before randomization'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Cohort 1 and Cohort 2 Placebo', 'description': 'Placebo: Placebo'}, {'id': 'FG001', 'title': 'Cohort 1 and Cohort 2 CTAP101 Capsule', 'description': 'CTAP101: CTAP101 Capsules is an extended-release (ER) oral formulation of calcifediol which was approved as Rayaldee® ER Capsules in June 2016 by the United States (US) Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI), defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Cohort 1 and Cohort 2 Placebo', 'description': 'Placebo: Placebo'}, {'id': 'BG001', 'title': 'Cohort 1 and Cohort 2 CTAP101 Capsule', 'description': 'CTAP101: CTAP101 Capsules is an extended-release (ER) oral formulation of calcifediol which was approved as Rayaldee® ER Capsules in June 2016 by the United States (US) Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI), defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years'}, {'title': 'Between 18 and 65 years'}, {'title': '>=65 years'}]}]}, {'title': 'Age, Continuous'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female'}, {'title': 'Male'}]}]}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native'}, {'title': 'Asian'}, {'title': 'Native Hawaiian or Other Pacific Islander'}, {'title': 'Black or African American'}, {'title': 'White'}, {'title': 'More than one race'}, {'title': 'Unknown or Not Reported'}]}]}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States'}], 'unitOfMeasure': 'participants'}], 'populationDescription': 'The study was terminated before randomization'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2022-01-11', 'size': 1694121, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2025-07-08T11:28', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SEQUENTIAL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 2}}, 'statusModule': {'whyStopped': 'FDA changed the post-marketing requirement necessitating a new study design and protocol.', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2023-01-31', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-07', 'completionDateStruct': {'date': '2024-06-19', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-07-08', 'studyFirstSubmitDate': '2022-09-13', 'resultsFirstSubmitDate': '2025-07-08', 'studyFirstSubmitQcDate': '2022-09-13', 'lastUpdatePostDateStruct': {'date': '2025-07-25', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2025-07-08', 'studyFirstPostDateStruct': {'date': '2022-09-16', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2025-07-25', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-06-19', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Numbers of Subjects Who Attained Mean Decrease in Plasma iPTH of 30% From Baseline', 'timeFrame': '26 weeks', 'description': 'The primary efficacy endpoint is the proportion of subjects in the intent-to- treat (ITT) population (age 8 to \\<18 years) attaining a mean decrease in plasma iPTH of at least 30% from pre-treatment baseline compared to placebo during the EAP.'}, {'measure': 'Safety and Tolerability', 'timeFrame': '26 weeks', 'description': 'Safety and tolerability will be evaluated in the safety population by AEs, PEs, VS, hematology and laboratory evaluations, and ECGs.'}, {'measure': 'Pharmacokinetic', 'timeFrame': '26 weeks', 'description': 'To assess the pharmacokinetic (PK) profile of 25-hydroxyvitamin D3 after repeated doses of CTAP101 Capsules in pediatric subjects'}], 'secondaryOutcomes': [{'measure': 'Level of Serum Total 25-hydroxyvitamin D at ≥30 ng/mL Compared to Placebo', 'timeFrame': '26 weeks', 'description': 'To evaluate the efficacy of repeated dosing with CTAP101 Capsules versus placebo in raising serum total 25-hydroxyvitamin D to ≥30 ng/mL'}, {'measure': 'Plasma iPTH Mean Absolute Changes and Serum Total 25-hydroxyvitamin D', 'timeFrame': '26 weeks', 'description': 'To determine the time courses of mean absolute changes from pre-treatment baseline in serum total 25-hydroxyvitamin D and plasma iPTH during administration of repeated doses of CTAP101 Capsules'}, {'measure': 'Pharmacodynamic Effects of Repeated Doses of CTAP101 Capsules', 'timeFrame': '26 weeks', 'description': 'To assess the PD effects of repeated doses of CTAP101 Capsules versus placebo on mean serum calcium (corrected for albumin), serum phosphorus and serum calcium-times-phosphorus (CaxP) product, and the change in mean urine calcium:creatinine ratio'}, {'measure': 'Incidence of Hypercalcemia and Hyperphosphatemia', 'timeFrame': '26 weeks', 'description': 'To evaluate the safety of CTAP101 Capsules versus placebo with regard to the incidence of hypercalcemia and hyperphosphatemia'}]}, 'oversightModule': {'isUsExport': True, 'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Chronic Kidney Disease stage3', 'Chronic Kidney Disease stage4', 'Vitamin d Deficiency', 'Secondary Hyperparathyroidism']}, 'descriptionModule': {'briefSummary': 'This is a phase 3, multi-center, randomized, double-blind, placebo-controlled study in children with stage 3-4 chronic kidney disease (CKD), secondary hyperparathyroidism (SHPT) and vitamin D insufficiency.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD'], 'maximumAge': '17 Years', 'minimumAge': '8 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Cohort 1: Be 12 to \\<18 years of age and have a body weight of ≥40 kg; Cohort 2: be 8 to \\<12 years of age and have a body weight of ≥20 kg.\n2. Be diagnosed with stage 3 to 4 CKD at least six months prior to the screening visit, and have an eGFR of ≥15 to \\<60 mL/min/1.73m2 at screening.\n3. Be without any disease state or physical condition that might impair evaluation of safety or which, in the investigator's opinion, would interfere with study participation, including:\n\n 1. Serum albumin ≤ 3.0 g/dL;\n 2. Serum transaminase (ALT or SGPT, AST or SGOT) \\> 2.5 times the upper limit of normal at screening; and,\n 3. Urinary albumin excretion of \\>3000 mcg/mg creatinine.\n4. Exhibit during the initial or, if necessary, a screening visit after washout:\n\n 1. Plasma iPTH \\>100 pg/mL (stage 3 CKD) or \\>160 pg/mL (stage 4 CKD)\n 2. Serum calcium \\<9.8 mg/dL (corrected for albumin);\n 3. Serum total 25-hydroxyvitamin D \\<30 ng/mL; and,\n 4. Serum phosphorus \\>2.5 to ≤5.5 mg/dL (12 to \\<18 years) or ≤6.0 mg/dL (ages 8 to \\<12 years).\n5. If taking calcitriol or other 1α-hydroxylated vitamin D analogs, or cinacalcet, be willing to forgo treatment with these agents for the duration of the study and complete an 8-week washout period prior to commencing treatment in the study.\n6. If taking \\>1,000 mg/day of elemental calcium, discontinue or reduce calcium use and/or use non-calcium based therapies for the duration of the study.\n7. If receiving ≤1,700 IU/day nutritional vitamin D (ergocalciferol or cholecalciferol) therapy, must agree to remain on a stable dose during the study.\n8. If taking \\>1,700 IU/day of nutritional vitamin D, must discontinue or decrease the dose to ≤1,700 IU/day, maintain that dose for the duration of the study, and complete an 8-week washout period prior to commencing treatment in the study provided that serum total 25-hydroxyvitamin D is ≥30 ng/mL. The washout period is not necessary if serum total 25-hydroxyvitamin D is \\<30 ng/mL.\n9. If taking any bone modifying treatment that could interfere with study endpoints, must discontinue use of such agent(s) for the duration of the study.\n10. Willing and able to comply with study instructions and commit to all clinic visits for the duration of the study.\n11. Female subjects of childbearing potential must be neither pregnant nor lactating and must have a negative urine pregnancy test at the first screening visit.\n12. All female subjects of childbearing potential and male subjects with female partners of childbearing potential must agree to use effective contraception (eg, implants, injectables, combined oral contraceptives, intrauterine device, sexual abstinence, vasectomy or vasectomized partner) for the duration of the study.\n13. Each subject or their legal representative must be able to read, understand and sign the informed consent form (ICF).\n\nExclusion Criteria:\n\n1. History of or planned kidney transplant or parathyroidectomy.\n2. History (prior three months) of serum calcium ≥9.8 mg/dL.\n3. Use of bisphosphonate therapy (denosumab) within six months prior to enrollment.\n4. Known previous or concomitant serious illness or medical condition, such as malignancy, human immunodeficiency virus, significant gastrointestinal or hepatic disease or cardiovascular event or hepatitis, or physical condition that in the opinion of the investigator may worsen and/or interfere with participation in the study.\n5. History of neurological/psychiatric disorder, including psychotic disorder, or any reason which, in the opinion of the investigator makes adherence to a treatment or follow up schedule unlikely.\n6. Known or suspected hypersensitivity to any of the constituents of either investigational product.\n7. Currently participating in, or has participated in, an interventional/investigational study within 30 days prior to study screening."}, 'identificationModule': {'nctId': 'NCT05543928', 'briefTitle': 'Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism', 'organization': {'class': 'INDUSTRY', 'fullName': 'OPKO Health, Inc.'}, 'officialTitle': 'A Multi-Center Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CTAP101 Extended-release Capsules to Treat Secondary Hyperparathyroidism in Pediatric Subjects of Ages 8 to <18 Years With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency', 'orgStudyIdInfo': {'id': 'CTAP101-CL-3007'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'PLACEBO_COMPARATOR', 'label': 'Cohort 1 and Cohort 2 Placebo', 'interventionNames': ['Drug: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'Cohort 1 and Cohort 2 CTAP101 Capsule', 'interventionNames': ['Drug: CTAP101']}], 'interventions': [{'name': 'CTAP101', 'type': 'DRUG', 'description': 'CTAP101 Capsules is an extended-release (ER) oral formulation of calcifediol which was approved as Rayaldee® ER Capsules in June 2016 by the United States (US) Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI), defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL.', 'armGroupLabels': ['Cohort 1 and Cohort 2 CTAP101 Capsule']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Placebo', 'armGroupLabels': ['Cohort 1 and Cohort 2 Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '43205', 'city': 'Columbus', 'state': 'Ohio', 'country': 'United States', 'facility': 'OPKO Study Site', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '29615', 'city': 'Greenville', 'state': 'South Carolina', 'country': 'United States', 'facility': 'OPKO Study Site', 'geoPoint': {'lat': 34.85262, 'lon': -82.39401}}], 'overallOfficials': [{'name': 'Akhtar Ashfaq, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'OPKO Health'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'OPKO Health, Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}